VKV. E. Kolesnikov

V. E. Kolesnikov

*This is an algorithmically generated author record based on publicly available information.

V. E. Kolesnikov has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In vivo study of the antitumor activity of indole-3-propionic acid and its combination with chemotherapy drugs

    by D. A. Lysenko, V. E. Kolesnikov, A. V. Galina, L. Yu. Vladimirova, A. N. Shevchenko, D. V. Khodakova, M. A. Kuznetsova, A. A. Shulga, S. N. Vlasov

    Background . Colorectal cancer (CRC) is characterized by high mortality and the development of therapy resistance. Indole-3-propionic acid (IPA), a gut microbiota-derived metabolite, shows promise in treating colorectal cancer (CRC) by strengthening antitumor immunity and improving chemotherapy effcacy. The aim of the study was to evaluate the antitumor activity of indole-3-propionate in vivo using a mouse model of colorectal cancer. Material and Methods . The experiment was conducted on 42 female mice with subcutaneous CT26 CRC. After reaching a tumor volume of 50–60 мм 3 , the animals were randomized into 6 groups (n=7): control (0.9 % NaCl saline i.p. and p.o.), IPA monotherapy (6 mg/kg, p.o.), 5-fuorouracil (5-FU) (25 mg/kg, i.p.), oxaliplatin (OXA) (10 mg/kg, i.p.), combination IPA (6 mg/kg, p.o.) + 5-FU (25 mg/kg, i.p.) and IPA (6 mg/kg, p.o.) + OXA (10 mg/kg, i.p.). Drugs were administered 3 times per week (Mon, Wed, Fri) for 3 weeks. The results were assessed one week after the end of treatment. Tumor volume and tumor growth inhibition (TGI) percentage were evaluated. Statistical analysis was performed using the Mann-Whitney U-test. Results . IPA monotherapy had no signifcant effect (TGI=5.0 %). Chemotherapeutic agents in monotherapy demonstrated moderate activity: TGI 22.9 % for 5-FU and 19.4 % for OXA. The greatest effcacy was achieved in the combination therapy groups: TGI 31.9 % for IPA + 5-FU and 30.1 % for IPA + OXA. Statistically signifcant growth inhibition in these groups was registered from day 18 (4 days earlier than with cytostatic monotherapy). Toxicity, assessed by body weight dynamics, was absent in all groups. Discussion . The results obtained demonstrate that IPA does not possess independent cytotoxic activity against CT26 tumor cells. However, its potential in combination with standard chemotherapeutic drugs was revealed. Earlier and more pronounced TGI in the combination therapy groups indicates the ability of IPA to accelerate the development of a therapeutic response. Conclusion . IPA potentiates the antitumor activity of 5-FU and OXA on the CT26 CRC model without increasing systemic toxicity. The obtained data justify further study of the mechanisms of IPA synergy with chemotherapeutic agents and its effcacy in other malignant neoplasms.

  • The influence of tumor sampling topology on the effectiveness of the xenotransplantation procedure in the creation of a PDX model of gastric cancer

    by D. V. Kamlyk, V. E. Kolesnikov, S. V. Gurova, A. V. Galina, I. V. Golovinov, D. V. Khodakova, A. A. Shulga

    As indicated in the extant literature, numerous research groups encounter challenges in creating PDX models of gastric cancer, which is associated with a low level of engraftment of tumor samples. Consequently, in the pursuit of enhancing and refining the conventional implantation technique, we have recognized the significance of the tumor sample collection site. It was hypothesized that cells located on the tumor periphery and forming the invasion front may have a more prjonounced potential for malignant growth and, consequently, the ability to grow as xenografts. To this end, ten gastric tumor samples were obtained from each patient: five from the tumor edges and five more from areas more than 5 mm from the visible tumor edge. All samples were implanted subcutaneously on the right side of Balb/C Nude mice. A subsequent analysis of the results indicated that, upon the collection of biological material concurrжent with the capture of the visible tumor edge, the formation of tumor nodules occurred in three out of five recipient animals. Consequently, the xenotransplantation efficiency in this instance was determined to be 84%. Conversely, when tissue samples were obtained from areas distant from the tumor edge, the formation of tumor nodules in recipient animals was observed in only one procedure out of five. Consequently, the xenotransplantation efficiency was 20%. The histological examination conducted as part of this study revealed that the heterotopic PDXs accurately reproduced the histotype of the corresponding donor tumors, confirming their adenocarcinoma status. We also conducted an IHC study, which demonstrated that the level of Ki-67 expression in the tumor edges forming the invasion front was significantly higher, with an average value of 70 [60; 80]%. Conversely, in samples extracted from non-marginal regions of the same tumor, Ki-67 expression levels were notably lower, with an average of 15% [5; 25%] (p<0.05). The obtained data suggest that the higher proliferative potential characterizing the marginal areas of tumors may contribute to more effective xenotransplantation of such tumor samples compared to samples obtained from areas of the tumor remote from the visible edge and characterized by a lower proliferative potential.


  • Open Access

    Modern strategy of metastatic colorectal cancer treatment (literature review)

    by O. I. Kit, Yu. A. Gevorkyan, N. V. Soldatkina, V. E. Kolesnikov, O. K. Bondarenko, A. V. Dashkov, Ю. А. Геворкян

    Современные хирургические стратегии лечения метастатического колоректального рака (обзор литературы)


  • D2 and D3 lymph node dissection for colon cancer

    by O.I. Kit, Yu.A. Gevorkyan, A.M. Karachun, N.V. Soldatkina, O.K. Bondarenko, V.E. Kolesnikov

    Objective. To evaluate surgical and oncological results of standard and extended lymph node dissection (D2 and D3) in patients with colon cancer. Material and methods. We analyzed treatment outcomes in 74 patients with colon cancer stage T1-4aN0-2M0 who underwent right- and left-sided hemicolectomy, resection of sigmoid colon with standard and extended lymph node dissection (D2 and D3). Results. Surgical approach and level of D3 lymph node dissection did not increase intra- and postoperative morbidity. Laparoscopic interventions were followed by significantly lower intraoperative blood loss and earlier gas discharge. Metastatic lesion of apical lymph nodes was observed in 5 out of 36 patients who underwent D3 lymph node dissection (13.8%), and metastases in regional lymph nodes rN1-2 were found in all these patients. Overall 5-year survival was 86%. Disease-free and overall 5-year survival were similar after D2 and D3 lymph node dissection. Conclusion. D3 lymph node dissection is safe for colon cancer. Metastatic lesions of apical lymph nodes during D3 lymph node dissection were detected only in patients with lesions of regional lymph nodes (rN1-2). Disease-free and overall 5-year survival were similar after D2 and D3 lymph node dissection.


  • Open Access

    Individual approach to metastatic colorectal cancer treatment (clinical cases)

    by O. I. Kit, Yu. A. Gevorkyan, N. V. Soldatkina, L. Yu. Vladimirova, I. L. Popova, O. K. Bondarenko, A. V. Dashkov, V. E. Kolesnikov, Ю. А. Геворкян

    Two patients with metastatic colorectal cancer underwent R0 large bowel resection followed by surgery liver and lungs metastases, retroperitoneal lymph nodes and post-op chemotherapy. The total follow-up period of the first patient was currently 12 years, the recurrence-free period was 5 years. In the second patient, stabilization of the disease was observed for 12 years, and the total follow-up period – 18.5 years. An integrated treatment approach to metastatic CRC with active surgery for removable distant metastases or perioperative use of the most effective drug therapy for potentially resectable metastases can control the disease even with an aggressive course.


  • Open Access

    Immediate and long-term results of the treatment of patients with rectal cancer

    by O. I. Kit, Yu. A. Gevorkyan, N. V. Soldatkina, V. E. Kolesnikov, O. K. Bondarenko, E. K. Khabzhokov, R. E. Tolmakh, A. V. Dashkov, D. S. Petrov, D. A. Savchenko, et al.

    The purpose of the study was to analyze rectal resection outcomes in patients with rectal cancer.Material and Methods. A retrospective analysis of treatment outcomes of 251 patients with stage cT3–4aN0–2M0 rectal cancer, who underwent transperitoneal resections of the rectum with mesorectumectomy from 2015 to 2020, was carried out. The age of the patients ranged from 27 to 90 years. Considering the extent of rectal tumor spread, 143 (56.9 %) patients underwent neoadjuvant prolonged conformal radiation therapy or chemoradiotherapy.Results. The failure of the colorectal anastomosis was observed in 11 (4.4 %) patients, repeated surgery was performed in 8 (72.7 %) patients (Grade C). During the follow-up, disease progression was detected in 58 (23.1 %) patients, tumor recurrence in the rectum occurred in 2 (0.8 %) patients, and distant metastases were found in 56 (22.3 %) patients. Statistical analysis showed that the parameters, such as the age, localization of the tumor in the rectum, tumor grade and T stage did not significantly affect the disease progression. A statistically significant relationship between the disease progression and pN2 stage was revealed. Patients with pN2 stage were 4.1 times more likely to have disease progression. The 75th percentile survival time was51.2 months. Patients with pN2 stage had a 3.6-fold increase in the risk of lethal outcome.Conclusion. The study demonstrated good oncological and surgical outcomes in the treatment of stage II–III rectal cancer with high survival rates. Resection of the rectum in patients with rectal cancer is a safe and predictable surgical procedure accompanied by a low incidence of anastomotic leaks and disease recurrence. The pN2 stage in rectal cancer patients significantly worsened the oncologic outcomes and survival of patients.


  • Open Access

    Overall survival in colon cancer patients with different levels of circulating tumor cells and feasibility of enhancing its prognostic value

    by O. I. Kit, E. Y. Zlatnik, I. A. Novikova, E. P. Ulianova, A. A. Demidova, E. N. Kolesnikov, Yu. A. Gevorkyan, N. V. Soldatkina, A. V. Snezhko

    Development of personalized approaches to diagnosis, treatment and prognosis of colon cancer (CC) still remains challenging. Levels of circulating tumor (CTC) and cancer stem cells (CSC) are promising non-invasive prognostic factors. Our aim was to assess the overall survival (OS) of patients with stage II–IV CC with different levels of CTCs as well as to enhance their prognostic value by additionally determining the level of CD44+ CSCs. Material and methods. The study included 299 patients with stage II–IV CC. All patients underwent surgery followed by adjuvant chemotherapy (FOLFOX). patients with stage IV CC with resectable liver metastases underwent simultaneous resection of the primary tumor and liver metastases, followed by FOLFOX chemotherapy. the proportion of CTCs was evaluated before surgery using Veridex CellSearch™, and the level of CD44+ CSCs was determined in the tissue of the removed tumor by the IHC method. OS was studied in patients with different CTC levels, cumulative OS was calculated by Kaplan–Meier`s method. prognostic algorithm was designed by logistic regression analysis and cox proportional hazards model. Results. OS was found to be lower in patients with higher CTC levels divided into ranges: 0, 1–3, 4–9, ≥10 (χ2=11.59, p=0.009); thus enabling us to use it for prognosis. its prognostic value is enhanced by estimation of CD44+ CSC in tumor. Statistically significant conjugation between CTC and CD44+ ranges was found. an increase in CTC level by 1 range resulted in the increase in the risk of fatal outcome by 1.58 times (р=0.002); the additive increase in CD44+ expression ≥10 % resulted in the increase in the risk of fatal outcome by 7.2 times (pConclusion. The prognostic algorithm for the risk of unfavorable outcome of patients with CC, based on the assessment of CTC and CD44+ CSC levels, was developed.

  • Open Access

    Bioresource collection of cell lines and primary tumors of the National Medical Research Center of Oncology of the Ministry of Health of Russia

    by S. V. Timofeeva, S. Yu. Filippova, A. O. Sitkovskaya, N. V. Gnennaya, I. V. Mezhevova, T. V. Shamova, L. M. Vashchenko, V. E. Kolesnikov, I. A. Novikova, O. I. Kit

    The Biobank of the National Medical Research Center of Oncology is a multi-layered infrastructure with large collections of biological samples, complemented by extensive and well-annotated clinical and pathological patient data, including medical images, pathological histology, and molecular analysis of biosamples. To date, the biobank of the National Medical Research Center of Oncology contains collections of primary and immortalized cancer cell lines of human origin. The collection of primary cell lines was formed from samples of postoperative material taken during the removal of tumors of various localizations (breast cancer, prostate cancer, lung cancer). All cell lines underwent internal quality control for contaminants (exogenous viruses, mycoplasmas and bacterial L-forms), viability and were cultivated without antibiotics. On the basis of the collected samples, a significant number of projects in the field of biomedicine were carried out, the results of which are described in this article.


  • Open Access

    Evaluation of the cytotoxic activity and toxicity of a tropolone derivative with a potential antitumor effect

    by O. I. Kit, V. I. Minkin, E. A. Lukbanova, Yu. A. Sayapin, E. A. Gusakov, A. O. Sitkovskaya, S. Yu. Filippova, E. F. Komarova, A. V. Volkova, D. V. Khodakova, et al.

    The aim. To study the toxicity of 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone in vitro and in vivo.Materials and methods. 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone was synthesized using a method for expanding the o-quinone cycle during the reaction between 5-nitro-2,6,8-trimethyl4-chloroquinoline and 3,4,5,6-tetrachloro-1,2-benzoquinone while boiled in dioxane. An in vitro experiment was carried out in the human A549 cell line. Cell viability was assessed using the MTT colorimetric assay by reducing the optical density of the experimental samples compared with the control ones. Acute toxicity was studied on 20 BALB/c Nude male mice. The test compound was administered once orally as a suspension in 1% starch gel at three doses: 0.0055 (group 1), 0.055 (group 2) and 0.55 mg / g (group 3). The control group (group 4) received a placebo.Results. We synthesized a new compound, 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone. Its structure was established by 1 H nuclear magnetic resonance (NMR), infrared (IR) spectroscopy, and mass spectrometry. The yield was 19.8 g (52%), the melting point was 205–207 ºС, bright yellow crystals (benzene) were observed. The half-maximal inhibitory concentration (IC50) of 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone was 0.21 ± 0.01 μM, which was significantly lower (р < 0.05) than the IC50 of cisplatin (3.84 ± 0.23). Following the in vivo experiment, no toxic effect of tropolone was detected when administered once at a dose of 0.0055, 0.055, and 0.55 mg / g. Conclusion. 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone demonstrated cytotoxic effects on the A549 cell line at a lower IC50 than cisplatin which is widely used in treatment of cancers, including lung cancer. Insolubility of 2-(6,8-dimethyl-5-nitro-4-chloroquinoline-2-yl)-5,6,7-trichloro-1,3-tropolone in water and the absence of its toxic effect in the studied modes determine the scope of its application for further study of cumulative and antitumor effects.


  • Open Access

    Results of surgical treatment for familial adenomatous polyposis

    by O. I. Kit, Yu. A. Gevorkyan, N. V. Soldatkina, E. N. Kolesnikov, V. E. Kolesnikov, O. K. Bondarenko, E. K. Khabzhokov, Ю. А. Геворкян

       Aim: to analyze the results of surgery for familial adenomatous polyposis (FAP).   Patients and methods: the case series study included 20 patients with FAP, 85 % of procedures with anastomosis and 15 % with a permanent ileostomy. Laparoscopic approach was used in 35 %.   Results: the mean time of operation time was 243 minutes, the mean intraoperative blood loss was 244 ml, and the mean hospital stay was 17.2. Three (15.0 %) patients developed postoperative complications. Laparoscopic pro­cedures were advantageous in terms of intraoperative blood loss and faster recovery. The first polyps were detected in the rectal stump within 6-8 months after surgery, desmoid tumors within 24.3 months. Most patients had an acceptable quality of life with an mean number of stools per day 11.1.   Conclusions: FAP is a complex problem of modern medicine requiring the teamwork of various medical specialists. Minimally invasive interventions for FAP have advantages over open procedures.